# Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown

> **Open Intelligence Dossier** · First detected: 2026-06-11 21:07 UTC · Category: Business

## Executive Summary
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.

## Intelligence Brief
"Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.


Outlets currently covering the story include FirstWord Pharma, Endpoints News, Business Wire and BioPharma Dive. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.


This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Verification URL |
|---|---|---|
| FirstWord Pharma | Takeda's oral TYK2 zasocitinib tops Sotyktu in Phase III showdown | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE9KV0J4ZW9YbU1pODV3MWc4N0lUdU1WRmotNlh4OUdZX2tHUVNOTDZrVGZwTUJZVmVuSl9zXzBLdGxtMFFhSldidm9lbUM4M1FIaTVr?oc=5) |
| Endpoints News | Takeda’s plaque psoriasis pill beats Bristol Myers’ Sotyktu in Phase 3 | [Source Link](https://news.google.com/rss/articles/CBMilgFBVV95cUxOUHZSZVphbXRWZW5VTXFvWHBKYVpLZWpaYU1pU1hnOUdwNHdldXhNS3c5MXJjSDNJSmFNQmtTOUZYblNjdmpzNzFSUUVBdUpEa3ZNNnBULUFGc3hSVWlxTXZnUHk5NWJNX0N0Y05PWmV1WjBVeFMwSXlubEh3Z1lfQ2NFZkI5ZEplWmVzSlR4TWtLOFVZbmc?oc=5) |
| Business Wire | Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations | [Source Link](https://news.google.com/rss/articles/CBMisgJBVV95cUxPdmowOTkxZHRwUGJLWGN3UHE3ZHplUFU4aDJMb0dDT0R6c2V0ZXp3dE9KajdNSGp1S0VESkxNd0lFbDh4QmJmaXVhM2tBWEJMaU94dDhZaUtTT2VXeFVsUWVVT1FHSXc2ZzdCb2lKLVJuTEhEN3RYMDFvQ2x4eC0xUVlmeWF5MjBNTHBUczBMZklHVkNucFAtZFp2aDlIVzB4NkRzOUNpZXVaR0VVU0otSEtmbFpDcjQxanZLZFVwclhqTXcwTWJXSy1GSi1haDhvVDI5OVE1ckQtMXBOTnJKNUVRVHFMcGZ2RmhMVTRrNzFIczFJclZ3WUNJazF3MU5DdkZvbXo2c0tMMXEwbTJPdkFNSmV5YmJvakhBWEJFNkVBUVFteWphWlJfNmpsc21uUGc?oc=5) |
| BioPharma Dive | Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test | [Source Link](https://news.google.com/rss/articles/CBMijgFBVV95cUxPZklTWHkzbEJ2S3UzU0pybFFHQ1pKcnlhSjJNajlDcUFrQkxhajJVazJIdGJhWXFlQng1aks0VXZ0d2piNnRTUWJXdzdabU9tYkhTWm5ybTdNVXRrSEJsdzBnUTJMVTl5cFZPMkVDVVdQUlJ3bC1QaXJTOGhQeU1uRU5fRDVDVVNIWmdJYWxR?oc=5) |
| Fierce Biotech | Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown | [Source Link](https://news.google.com/rss/articles/CBMiqwFBVV95cUxOelVSMUFobHRnMjNTNUx5cnM3QkdkRmRTRk03eG84S3BoZkdRbG1tbEdZY2VmRVVBTE5WQlJvb0lPY2Q1eFMyRXpCdElwbU1Ed3hzNkMyX3JTZjVCT29xTU5xd1QzY1VQYWVUREthNmRjbkNidXQ5YjB4VlJFQXFwRTNTdUttYXFlUFJHTXhfaTlHdGFSLWpnSGR2T1RzVWFTVVhpWXNfM05RNXM?oc=5) |

---
*Canonical Source: https://pulse.byoviral.com/trend/2026-06-11/takeda-s-tyk2-inhibitor-beats-bristol-myers-sotyktu-in-phase-3-psoriasis*